Company intelligence / Profile preview

Lytix Biopharma

Ownership: Public · LYTIX
Employees: ~8
Development stage: Phase 2

Overview

LTX-315 achieved 97% calculated objective response rate in Phase II study for basal cell carcinoma; 40% disease control in late-stage melanoma with response lasting up to 22 months in ATLAS-IT-05 study; preparing for Phase III discussions with FDA in H1 2025

Therapeutic areas: Oncology
Modalities: Oncolytic peptideshost-defense peptide-derived molecules
Industry: Biotech

Drug pipeline

4 assets

voxvoganan

3 more assets in the full pipeline.

Request access →

Partnerships

Verrica Pharmaceuticals Inc.

Financials

Market cap: $6M
Total revenue: $1.5M
Enterprise value: $7.3M

Beyond the preview

Go deeper on Lytix Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lytix Biopharma.

Explore the full profile